On the spotlight

Project Objectives The project aims at investigating the potential role of different InMed Pharmaceuticals proprietary compounds on the modulation of the various elements of the endocannabinoid system in human keratinocytes, in order to use them as a new therapeutical strategy to cure skin conditions like tumors, psoriasis, atopic dermatitis, acne vulgaris, seborrhea and itchy skin. Start/End&nb...

Focus on

Pathogenic mechanisms and therapeutic potential Project Objectives The project focuses on the role of the endocannabinoid degrading enzyme FAAH (fatty acid amide hydrolase) as a potential molecular target in Alzheimer’s disease, in order to: i) better understand the pathogenic mechanisms of this condition; ii) identify early symptoms of the disease; and iii) develop new therapeutic strategies....
Project Objectives The project aims at exploring the ability of new chemical entities to inhibit monoacylglycerol lipase (MAGL), a key enzyme that regulates the production of inflammatory mediators that are synthesized from arachidonic acid, and from the endocannabinoid 2-arachidonoylglycerol. Start/End date 2018 - 2019 Principal Investigator Prof. Mauro Maccarrone - Coordinator Ho...
Project Objectives The projects aims at studying the ability of crucial specialized pro-resolving lipid mediators, such as resolving D1, resolving D2 and maresin 1, to restore the altered balance between regulatory T cells and effector T cells in patients with multiple sclerosis. In particular, the capacity of these molecules to modulate the inflammatory responses driven by these adaptive immune ...